Literature DB >> 20668477

Hematology: Is thalidomide combination a new option for myeloma?

Antonio Palumbo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20668477     DOI： 10.1038/nrclinonc.2010.86

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

Authors:  Mauricio Pineda-Roman; Maurizio Zangari; Jeff Haessler; Elias Anaissie; Guido Tricot; Frits van Rhee; John Crowley; John D Shaughnessy; Bart Barlogie
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

2.  Multiple myeloma in the era of novel agents.

Authors:  Meletios A Dimopoulos; Michel Attal
Journal:  Semin Hematol       Date:  2009-04       Impact factor: 3.851

3.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.

Authors:  Bart Barlogie; Michel Attal; John Crowley; Frits van Rhee; Jackie Szymonifka; Philippe Moreau; Brian G M Durie; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

4.  A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.

Authors:  Henk M Lokhorst; Bronno van der Holt; Sonja Zweegman; Edo Vellenga; Sandra Croockewit; Marinus H van Oers; Peter von dem Borne; Pierre Wijermans; Ron Schaafsma; Okke de Weerdt; Shulamiet Wittebol; Michel Delforge; Henriëtte Berenschot; Gerard M Bos; Kon-Siong G Jie; Harm Sinnige; Marinus van Marwijk-Kooy; Peter Joosten; Monique C Minnema; Rianne van Ammerlaan; Pieter Sonneveld
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

5.  Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

Authors:  Bart Barlogie; Mauricio Pineda-Roman; Frits van Rhee; Jeff Haessler; Elias Anaissie; Klaus Hollmig; Yazan Alsayed; Sarah Waheed; Nathan Petty; Joshua Epstein; John D Shaughnessy; Guido Tricot; Maurizio Zangari; Jerome Zeldis; Sol Barer; John Crowley
Journal:  Blood       Date:  2008-05-20       Impact factor: 22.113

6.  Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Authors:  Antonio Palumbo; Francesca Gay; Patrizia Falco; Claudia Crippa; Vittorio Montefusco; Francesca Patriarca; Fausto Rossini; Simona Caltagirone; Giulia Benevolo; Norbert Pescosta; Tommasina Guglielmelli; Sara Bringhen; Massimo Offidani; Nicola Giuliani; Maria Teresa Petrucci; Pellegrino Musto; Anna Marina Liberati; Giuseppe Rossi; Paolo Corradini; Mario Boccadoro
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.